Sachin Jain
Stock Analyst at Bank of America Securities
(3.12)
# 2,448
Out of 4,334 analysts
244
Total ratings
54%
Success rate
2.5%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | $16,500 | $13,916.00 | +18.57% | 75 | May 21, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | $140 | $119.46 | +17.19% | 19 | May 11, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | $92 | $77.46 | +18.77% | 19 | Apr 23, 2026 | |
| NVS Novartis AG | Reiterated: Buy | $111 → $140 | $152.01 | -7.90% | 2 | Mar 27, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | $2,100 → $2,350 | $1,915.00 | +22.72% | 11 | Feb 9, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | $340 → $350 | $289.00 | +21.11% | 27 | Feb 5, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | $30 → $35 | $38.41 | -8.88% | 9 | Dec 2, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | $1,950 → $2,250 | $1,723.63 | +30.54% | 23 | Nov 25, 2025 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | $11 | $9.70 | +9.32% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $1,700 | $51.38 | +3,208.68% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $910 → $375 | $44.96 | +734.07% | 37 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $275 → $340 | $334.50 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $205 | $130.00 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $26.88 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $24 | $23.43 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $195 | $46.88 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $25.90 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $179.24 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
May 21, 2026
Reiterated: Buy
Price Target: $16,500
Current: $13,916.00
Upside: +18.57%
Novartis AG
May 11, 2026
Reiterated: Buy
Price Target: $140
Current: $119.46
Upside: +17.19%
Sanofi
Apr 23, 2026
Reiterated: Hold
Price Target: $92
Current: $77.46
Upside: +18.77%
Novartis AG
Mar 27, 2026
Reiterated: Buy
Price Target: $111 → $140
Current: $152.01
Upside: -7.90%
GSK plc
Feb 9, 2026
Reiterated: Hold
Price Target: $2,100 → $2,350
Current: $1,915.00
Upside: +22.72%
Novo Nordisk A/S
Feb 5, 2026
Maintained: Hold
Price Target: $340 → $350
Current: $289.00
Upside: +21.11%
Bayer Aktiengesellschaft
Dec 2, 2025
Maintained: Buy
Price Target: $30 → $35
Current: $38.41
Upside: -8.88%
Genmab A/S
Nov 25, 2025
Maintained: Buy
Price Target: $1,950 → $2,250
Current: $1,723.63
Upside: +30.54%
Grifols, S.A.
Nov 25, 2025
Maintained: Buy
Price Target: $11
Current: $9.70
Upside: +9.32%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $1,700
Current: $51.38
Upside: +3,208.68%
Oct 9, 2025
Maintained: Hold
Price Target: $910 → $375
Current: $44.96
Upside: +734.07%
Sep 13, 2024
Upgraded: Buy
Price Target: $275 → $340
Current: $334.50
Upside: n/a
Jun 12, 2023
Maintained: Buy
Price Target: $110 → $205
Current: $130.00
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $26.88
Upside: n/a
Feb 2, 2023
Maintained: Hold
Price Target: $24
Current: $23.43
Upside: n/a
Jan 17, 2023
Maintained: Hold
Price Target: $195
Current: $46.88
Upside: n/a
Nov 1, 2022
Maintained: Buy
Price Target: $60
Current: $25.90
Upside: n/a
May 2, 2016
Maintained: Buy
Price Target: n/a
Current: $179.24
Upside: n/a